Guidance

Shingles vaccine (Shingrix®): patient group direction (PGD) template

PGD template for Shingrix® vaccine for immunocompromised individuals.

• From: UK Health Security Agency
• Published: 31 August 2021
• Last updated: 15 November 2024 — See all updates

Applies to England

Documents

Shingles vaccine (Shingrix®) PGD template

Ref: UKHSA gateway number GOV-14999

MS Word Document, 185 KB

This file may not be suitable for users of assistive technology.

Request an accessible format.

If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Details

This patient group direction (PGD) template is to support the administration of Shingrix® vaccine in accordance with the national shingles immunisation programme.

It is valid from 1 September 2023 to 30 September 2025, incorporating the changes to the national programme for immunocompetent adults aged 65 and over.

Practitioners must not use this PGD template until it has been authorised in Section 2. This is a legal requirement (see Human Medicines Regulations 2012). Practitioners should follow local policy or procedures to access authorised PGD documents.

This PGD template should be used with reference to current national guidance, the Green Book, and Summary of Product Characteristics for the vaccine.

Published 31 August 2021
Last updated 15 November 2024 + show all updates

1. 15 November 2024

   Removed link to Zostavax PGD because this has expired.

2. 18 July 2023

   Added version 2.00 – see page 2 for change history.

3. 31 August 2021

   First published.